2016 Oncology Measures Group Overview

The Oncology Measures Group is a reporting option that significantly reduces the burden of participation in the Physician Quality Reporting System (PQRS).

Source: 2016 Physician Quality Reporting System (PQRS) Measures Groups Specifications Manual: 
<table>
<thead>
<tr>
<th>Reporting Requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>20 Patient Sample Method</strong></td>
</tr>
<tr>
<td>• A minimum of 20 unique patients.</td>
</tr>
<tr>
<td>• Minimum 11 of the 20 must be Medicare Part B fee-for-service (FFS) patients.</td>
</tr>
<tr>
<td>• Be 18 years old or older.</td>
</tr>
<tr>
<td>• Have a <strong>specific diagnosis of cancer</strong>.</td>
</tr>
<tr>
<td>• Billed one of the following radiation treatment management CPT codes: 77427, 77431, 77432, 77435, or 77470</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reporting Periods</th>
</tr>
</thead>
<tbody>
<tr>
<td>• January 1, 2016 – December 31, 2016</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>• There are a total of 7 measures in the Oncology Measures Group.</td>
</tr>
<tr>
<td>• All applicable measures must be reported at least once (for at least one patient that meets the denominator criteria for a measure).</td>
</tr>
<tr>
<td>• The quality actions for each applicable measure must be performed at least once during the reporting period.</td>
</tr>
</tbody>
</table>
• **71 Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer.**

• **72 Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients.**

• **110 Preventive Care and Screening: Influenza Immunization.**

• **130 Documentation of Current Medications in the Medical Record.**

• **143 Oncology: Medical and Radiation – Pain Intensity Quantified.**

• **144 Oncology: Medical and Radiation – Plan of Care for Pain.**

• **226 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention.**
Reporting Options

Performance Met
- Successful reporting and completion of the measure.
- Documentation of measure requirements/description.

Medical Performance Exclusion
- Documented medical reason why measure requirements are not met.
- Patient is excluded from the performance denominator for this measure.

Patient Performance Exclusion
- Documented patient reason why measure requirements are not met.
- Example: Patient refusal of prescription or immunization.
- Patient is excluded from the performance denominator for this measure.

System Performance Exclusion
- Documented system reason (non-medical or patient reason) why the measure requirements are not met.
- Example: Patient is in enrolled in a clinical trial.
- Patient is excluded from the performance denominator for this measure.

Performance Not Met
- NO reason why measure requirement was not met.
- Indicates unsuccessful performance and does not fulfill measure requirements
# 71 Breast Cancer: Hormonal Therapy for Stage IC-IIIC ER/PR Positive Breast Cancer

<table>
<thead>
<tr>
<th>Measure Description</th>
<th>Patients who fall into denominator for this measure (measures is applicable)</th>
<th>Reporting Options</th>
<th>Other Information</th>
</tr>
</thead>
</table>
| Percentage of female patients 18 and older with Stage IC-IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the reporting period. | - Female 18 years old or older, AND  
- Has AJCC Stage IC-IIIC breast cancer, AND:  
  - Applicable diagnosis codes: C50.011, C50.012, C50.019, C50.111, C50.112, C50.119, C50.211, C50.212, C50.219, C50.311, C50.312, C50.319, C50.411, C50.412, C50.419, C50.511, C50.512, C50.519, C50.611, C50.612, C50.619, C50.811, C50.812, C50.819, C50.911, C50.912, C50.919  
  - Patient encounter during the reporting period (CPT): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215  
- Is ER or PR positive to breast cancer.  
- Patient seen during 2016 reporting period. | **Performance Met:** Tamoxifen or aromatase inhibitor prescribed.  
**Medical Performance Exclusion:** If Tamoxifen or AI were not prescribed, then documentation must indicate a medical reason for why not.  
**Patient Performance Exclusion:** Documentation of patient reasons for not prescribing tamoxifen or AI (patient refusal or other reasons)  
**System Performance Exclusion:** Documentation provided of system reasons for not prescribing tamoxifen or AI (e.g., patient is currently enrolled in clinical trial)  
**Performance NOT Met:** Tamoxifen or AI not prescribed, no reason provided | - Prescribed may include prescription given to patient for tamoxifen or AI at one or more visits during the reporting period OR patient already taking tamoxifen or AI as documented in the current medication list. |
# 72 Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients

<table>
<thead>
<tr>
<th>Measure Description</th>
<th>Percentage of patients aged 18 through 80 years with AJCC Stage III colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the reporting period.</th>
</tr>
</thead>
</table>
| Patients who fall into denominator for this measure (measures is applicable) | • 18-80 years old, AND  
• Has AJCC Stage IIIC colon cancer, AND  
  ▪ Applicable diagnosis codes: C18.0, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9 |
| Reporting Options | **Performance Met:** Adjuvant chemotherapy was referred, prescribed or previously received for AJCC Stage III colon cancer  
**Performance Exclusion:** Documented reasons for why adjuvant chemotherapy was not prescribed or previously received (e.g., co-morbidities or other reasons)  
**Performance Not Met:** No reason given/documentated as to why adjuvant chemotherapy was not prescribed or received |
| Other Information | • This measure may not be applicable to many radiation oncologists’ patients. It is possible that no patients meet the denominator criteria for this measure.  
• Prescribed may include prescription ordered for the patient for adjuvant chemotherapy at one or more visits in the 12 month period OR patient already receiving adjuvant chemotherapy as documented in the current medication list. |

[Back to measures list.](#)
## 110 Preventive Care and Screening: Influenza Immunization

<table>
<thead>
<tr>
<th>Measure Description</th>
<th>Percentage of patients aged 6 months and older, seen during the flu season who received an influenza immunization OR who reported previous receipt of an influenza immunization.</th>
</tr>
</thead>
</table>
| Patients who fall into denominator for this measure (measures is applicable) | • 18 years or older AND  
• Patient seen once January 1, 2016 – March 31, 2016, or October 1, 2016 - December 31, 2016. |
| Reporting Options | **Performance Met:** Influenza immunization received or previously received by another physician during the current flu season  
**Performance Exclusion:** Influenza immunization was not administered due to reasons documented by the physician (e.g., patient refusal, etc.)  
**Performance Not Met:** Influenza immunization was not given, no reason documented |
| Other Information | • If patient visit date is between April 1, 2016, and September 31, 2016, the measure is not applicable.  
• Immunizations administered during the month of August or September can be reported when a visit happens during the flu season.  
• Immunization must be documented for at least one patient if patients are seen between January and March, and October and December.  
• Previous receipt is the receipt of current season’s influenza immunization from another provider OR from same provider prior to the visit to which the measure is applied (typically, prior vaccination would include influenza vaccine given since August 1). |
## 130 Documentation of Current Medications in the Medical Record

<table>
<thead>
<tr>
<th>Measure Description</th>
<th>Patients aged 18 years and older for which the provider attests to documenting a list of current medications using all immediate resources available on the date of the encounter.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients who fall into denominator for this measure (measures is applicable)</td>
<td>All visits for patients aged 18 years or older</td>
</tr>
<tr>
<td><strong>Reporting Options</strong></td>
<td><strong>Performance Met:</strong> Provider attests to documenting that they obtained, updated, or reviewed medications that the patient is taking. <strong>Performance Exclusion:</strong> Provider attests to documenting any medications being obtained, updated, or reviewed, that the patient is not eligible for. <strong>Performance Not Met:</strong> Current list of medications are not documented by the physician. No reason provided.</td>
</tr>
<tr>
<td><strong>Other Information</strong></td>
<td>• Current medications must be documented for at least one patient. • Current medications include all prescriptions, over-the-counters, herbals and vitamin/mineral/dietary (nutritional) supplements with each medication’s name, dosage, frequency and administered route.</td>
</tr>
</tbody>
</table>
### Measure Description

Patients with a diagnosis of cancer, regardless of age, currently receiving chemotherapy or radiation therapy in which pain intensity is quantified.

### Patients who fall into denominator for this measure (measures is applicable)

- Patient with a [diagnosis of cancer](#) currently receiving chemotherapy or radiation therapy
- Patient seen during 2016 reporting period

### Reporting Options

**Performance Met:** Pain severity quantified; pain present

**Performance Met:** Pain severity quantified; pain not present

**Performance Not Met:** Pain severity not documented, reason not otherwise specified

### Other Information

- Pain must be quantified for at least one patient using a standard scale, such as 0-10 numerical rating scale, visual analog scale, a categorical scale or pictorial scale.
## 144 Oncology: Medical and Radiation – Plan of Care for Pain

<table>
<thead>
<tr>
<th>Measure Description</th>
<th>Patients with a diagnosis of cancer currently receiving chemotherapy or radiation therapy, regardless of age, who report having pain with a documented plan of care to address the pain.</th>
</tr>
</thead>
</table>
| Patients who fall into denominator for this measure (measures is applicable) | • Patient with a diagnosis of cancer.  
• Pain intensity has been quantified using a standard scale, such as 0-10 numerical rating scale.  
• Patient seen during 2016 reporting period. |
| Reporting Options | **Performance Met:** Documentation of Plan of care to address patient pain.  
**Performance Not Met:** Plan of care not documented, no reason provided. |
| Other Information | • This measure is ONLY to be reported if pain was present for measure #143 – Oncology: Medical and Radiation – Pain Intensity Quantified. DO NOT REPORT if no pain present for measure #143.  
• Plan of care must be documented for at least one patient for whom pain was present as identified in measure #143.  
• Plan of care for pain may include use of prescriptions for pain relief, psychological support, patient/family education, or referral to a pain clinic. |
### 226 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

<table>
<thead>
<tr>
<th>Measure Description</th>
<th>Patients, 18 or older, who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user.</th>
</tr>
</thead>
</table>
| Patients who fall into denominator for this measure (measures is applicable) | - 18 years old or older.  
  - Patient seen during 2016 reporting period. |
| Reporting Options | **Performance Met:** Patient screened for tobacco use AND received tobacco cessation intervention if identified as a tobacco user  
**Performance Met:** Patient is not a current tobacco user  
**Medical Performance Exclusion:** Documentation of medical reason for not screening for tobacco use (limited life expectancy or other reasons)  
**Performance Not Met:** Tobacco screening OR tobacco cessation intervention not performed, reason not given |
| Other Information | - Tobacco use screening and cessation intervention must be reported for at least one patient.  
  - Tobacco use includes any type of tobacco.  
  - Counseling intervention includes brief counseling (three minutes or less), and/or pharmacotherapy. |
One of the following diagnosis codes indicating cancer:

CONTINUED ON NEXT SLIDES.

ICD-10-CM: C00.0, C00.1, C00.2, C00.3, C00.4, C00.5, C00.6, C00.8, C00.9, C01, C02.0, C02.1, C02.2, C02.3, C02.4, C02.8, C02.9, C03.0, C03.1, C03.9, C04.0, C04.1, C04.8, C04.9, C05.0, C05.1, C05.2, C05.8, C05.9, C06.0, C06.1, C06.2, C06.80, C06.89, C06.9, C07, C08.0, C08.1, C08.9, C09.0, C09.1, C09.8, C09.9, C10.0, C10.1, C10.2, C10.3, C10.4, C10.8, C10.9, C11.0, C11.1, C11.2, C11.3, C11.8, C11.9, C12, C13.0, C13.1, C13.2, C13.8, C13.9, C14.0, C14.2, C14.8, C15.3, C15.4, C15.5, C15.8, C15.9, C16.0, C16.1, C16.2, C16.3, C16.4, C16.5, C16.6, C16.8, C16.9, C17.0, C17.1, C17.2, C17.3, C17.8, C17.9, C18.0, C18.1, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C19, C20, C21.0, C21.1, C21.2, C21.8, C22.0, C22.1, C22.2, C22.3, C22.4, C22.7, C22.8, C22.9, C23, C24.0, C24.1, C24.8, C24.9, C25.0, C25.1, C25.2, C25.3, C25.4, C25.7, C25.8, C25.9, C26.0, C26.1, C26.9, C30.0, C30.1, C31.0, C31.1, C31.2, C31.3, C31.8, C31.9, C32.0, C32.1, C32.2, C32.3, C32.8, C32.9, C33, C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.83, C34.91, C34.92, C37, C38.0, C38.1, C38.3, C38.4, C38.8, C39.0, C39.9, C40.00, C40.01, C40.02, C40.10, C40.11, C40.12, C40.20, C40.21, C40.22, C40.30, C40.31, C40.32, C40.80, C40.81, C40.82, C40.90, C40.91, C40.92, C41.0, C41.1, C41.2, C41.3, C41.4, C41.9, C43.0, C43.10, C43.11, C43.12, C43.20, C43.21, C43.22, C43.30, C43.31, C43.39, C43.4, C43.51, C43.52, C43.59, C43.60, C43.61, C43.62, C43.70, C43.71, C43.72, C43.8, C43.9, C44.00, C44.01, C44.02, C44.09, C44.101, C44.102, C44.109, C44.111, C44.112, C44.119, C44.121, C44.122, C44.129, C44.191, C44.192, C44.199, C44.201, C44.202, C44.209, C44.211, C44.212, C44.219, C44.221, C44.222, C44.229, C44.291, C44.292, C44.299, C44.300, C44.301, C44.309, C44.310, C44.311, C44.319, C44.320, C44.321, C44.329, C44.390, C44.391, C44.399, C44.40, C44.41, C44.42, C44.49, C44.500, C44.501, C44.509, C44.510, C44.511, C44.519, C44.520, C44.521, C44.529, C44.590, C44.591, C44.599, C44.601, C44.602, C44.609, C44.611, C44.612, C44.619, C44.621, C44.622, C44.629, C44.691, C44.692, C44.699, C44.701, C44.702, C44.709, C44.711, C44.712, Version 9.1 12/18/2015 Page 295 of 471 CPT only copyright 2015 American Medical Association. All rights reserved. C44.719, C44.721, C44.722, C44.729, C44.791, C44.792, C44.799, C44.80, C44.81, C44.82, C44.89, C44.90, C44.91, C44.92, C44.99, C45.0, C45.1, C45.2, C45.7, C45.9, C46.0, C46.1, C46.2, C46.3, C46.4, C46.50, C46.51, C46.52, C46.7, C46.9, C47.0, C47.10, C47.11, C47.12, C47.20, C47.21, C47.22, C47.3, C47.4, C47.5, C47.6, C47.8, C47.9, C48.0, C48.1, C48.2, C48.8, C49.0, C49.10, C49.11, C49.12, C49.20, C49.21, C49.22, C49.3, C49.4, C49.5, C49.6, C49.8, C49.9, C4A.0, C4A.10, C4A.11, C4A.12, C4A.20, C4A.21, C4A.22, C4A.30, C4A.31, C4A.39, C4A.4, C4A.51, C4A.52, C4A.59, C4A.60, C4A.61, C4A.62, C4A.70, C4A.71, C4A.72, C4A.8, C4A.9, C50.011, C50.012, C50.019,